However, in this study, we showed that after 1 week of treatment with the studied anticoagulants, asymptomatic deep vein thrombosis was more common in patients receiving the FXa inhibitor rivaroxaban (29%), less common in patients receiving dabigatran etexilate (11%), and was absent from the nadroparin group (Supplementary Table S2[available in the online version only]). The gene discussed is F10; the disease is deep vein thrombosis.